United Therapeutics Slips as New Sell Rating Pressures Shares

United Therapeutics Corporation (UTHR) is down 3.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be a fresh Sell initiation that challenged the stock’s valuation and raised doubts about how much future growth is already reflected in the shares. The decline may also reflect lingering investor sensitivity to reimbursement, generic competition, and execution risk around newer growth products.

Details:

A major bank initiated coverage on United Therapeutics with a Sell rating and a $321 price target, arguing the shares trade above their long-term valuation range despite pressure on the company’s older business.

The note highlighted risk that payer dynamics, generic entry, and real-world adoption issues could limit the expected contribution from Jenraldi, one of the company’s newer growth drivers.

United Therapeutics disclosed earlier this month that it is using the remainder of its $2 billion repurchase authorization through an accelerated share repurchase, a move that can support the stock but may also sharpen debate over capital allocation and valuation.

In its recent quarterly filing, the company continued to flag pricing and reimbursement pressure, generic competition, and the need to secure broader coverage for nebulized Tyvaso in idiopathic pulmonary fibrosis as important business risks.

Sources:

Investing.com, SEC, United Therapeutics Investor Relations

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$UTHR Insider Trading Activity

$UTHR insiders have traded $UTHR stock on the open market 1542 times in the past 6 months. Of those trades, 0 have been purchases and 1542 have been sales.

Here’s a breakdown of recent trading of $UTHR stock by insiders over the last 6 months:

MARTINE A ROTHBLATT (Chairperson & CEO) has made 0 purchases and 1181 sales selling 1,073,500 shares for an estimated $581,150,520.
JAMES EDGEMOND (CFO AND TREASURER) has made 0 purchases and 255 sales selling 228,750 shares for an estimated $128,757,897.
PAUL A MAHON (EVP & GENERAL COUNSEL) has made 0 purchases and 96 sales selling 91,300 shares for an estimated $49,254,897.
CHRISTOPHER PATUSKY has made 0 purchases and 2 sales selling 3,910 shares for an estimated $2,234,670.
TOMMY G THOMPSON has made 0 purchases and 3 sales selling 2,000 shares for an estimated $1,078,332.
CHRISTOPHER CAUSEY sold 1,300 shares for an estimated $786,032
NILDA MESA has made 0 purchases and 3 sales selling 486 shares for an estimated $265,477.
JAN MALCOLM sold 325 shares for an estimated $178,941

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$UTHR Hedge Fund Activity

We have seen 424 institutional investors add shares of $UTHR stock to their portfolio, and 456 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

WELLINGTON MANAGEMENT GROUP LLP removed 885,222 shares (-39.1%) from their portfolio in Q2 2026, for an estimated $479,639,836
VESTAL POINT CAPITAL, LP added 360,000 shares (+480.0%) to their portfolio in Q2 2026, for an estimated $195,058,800
D. E. SHAW & CO., INC. removed 306,971 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $166,326,096
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 297,162 shares (+inf%) to their portfolio in Q2 2026, for an estimated $161,011,286
JANE STREET GROUP, LLC added 283,167 shares (+10263.4%) to their portfolio in Q2 2026, for an estimated $153,428,375
AQR CAPITAL MANAGEMENT LLC removed 280,224 shares (-33.9%) from their portfolio in Q2 2026, for an estimated $151,833,769
JPMORGAN CHASE & CO added 275,358 shares (+inf%) to their portfolio in Q2 2026, for an estimated $149,197,225

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$UTHR Government Contracts

We have seen $1,573,798 of award payments to $UTHR over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

TYVASO KITS & CARTRIDGES: $379,307
PATIENT MEDICATION OF TYVASO 80MG - SHIPPING TO THE BALTIMORE VA MEDICAL CENTER PHARMACY.: $33,158
PATIENT MEDICATION ORDER OF TYVASO 80MG FOR THE BALTIMORE VA MEDICAL CENTER PHARMACY.: $33,158
TYVASO 80 MCG: $33,158

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$UTHR Price Targets

Multiple analysts have issued price targets for $UTHR recently. We have seen 6 analysts offer price targets for $UTHR in the last 6 months, with a median target of $660.0.

Here are some recent targets:

Lisa Walter from RBC Capital set a target price of $704.0 on 07/07/2026
Benjamin Burnett from Wells Fargo set a target price of $738.0 on 05/07/2026
Terence Flynn from Morgan Stanley set a target price of $519.0 on 04/10/2026
Greg Harrison from B of A Securities set a target price of $626.0 on 03/31/2026
Andrew S. Fein from HC Wainwright & Co. set a target price of $660.0 on 03/31/2026
Joseph Thome from TD Cowen set a target price of $660.0 on 03/30/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.